A recombinant oncolytic virus encoding either an adenosine deaminase or heterologous proteins can be used in treatment of a variety of diseases, as the primary purpose of these are to maintain and develop the immune system. A team of researchers at Nationwide Children’s Hospital have found a method that can address the delivery of adenosine deaminase into cancer cells, immune cells and the tumor microenvironment to aid in treatment for any disease or condition associated with adenosine or other associated markers.